A randomized, placebo controlled, double blinded, parallel group clinical study to evaluate the efficacy and safety of AEV01 along with standard care for elderly patients with mild COVID-19

Balan, Aravinda Kumar; Kannan, Ramesh; Muralikumar, Vanitha; Annam, Vamseedhar; Murugesan, Sakthi Balan; Sekhar, MM; Medasani, Renu

doi:10.1016/j.jaim.2023.100860

Journal of Ayurveda and Integrative Medicine

2024

DOI: 10.1016/j.jaim.2023.100860

|View full text |Cite

A randomized, placebo controlled, double blinded, parallel group clinical study to evaluate the efficacy and safety of AEV01 along with standard care for elderly patients with mild COVID-19

Aravinda Kumar Balan,

Ramesh Kannan,

Vanitha Muralikumar

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Preprint2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Evaluating the Anti-Tumor Efficacy and Safety of AEV01 in Glioblastoma and Hepatocellular Carcinoma: AnIn VitroandIn VivoApproach

Biswas,

Precilla S,

Kumar

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Gliomas and hepatocellular carcinoma (HCC) are difficult to treat with short survival rates despite current therapies. The need for new treatments is urgent, and orthotopic cell-derived tumor xenograft (CDX) models have provided valuable insights. AEV01, a specialty extract from the roots of Picrorhiza kurroa, shows promise as a non-surgical treatment option with anti-inflammatory, antioxidant, and anti-cancer properties. Its efficacy has been demonstrated in a patient with pancreatic cancer and in enhancing immune conditions in COVID-19 patients. Objectives: This study was conducted with the objective to investigate the anti-tumour properties of AEV01 in human glioblastoma and liver cancer cells through in vitro and in vivo experiments. Methodology: The methodology of the study involved the use of various cell lines including HEK-293T, U-87 MG glioblastoma, HepG2 liver cancer, Hep3B, and WRL-68 liver senescence cells. The cytotoxicity of the drug AEV01 was assessed using the MTT assay. Dual staining with acridine orange/ethidium bromide was performed to evaluate morphological changes in the cancer cells. ELISA was used to detect protein marker expression levels. Immunocytochemistry was employed to assess CD36 expression in various cellular models. Orthotopic tumor engraftment was carried out to establish a glioblastoma-induced model. Animal grouping and treatment plans were done, and histopathological effects were evaluated. Immunohistochemistry was performed to assess the anti-tumor effects of AEV01. ELISA and toxicity studies were also conducted. Results: The results of the study showed that AEV01 had dose-dependent cytotoxicity against glioma and liver cancer cells, while minimally impacting normal cells. AEV01 induced apoptosis in cancer cells and downregulated the expression of inflammatory markers while upregulating the expression of the tumor suppressor protein TP53. AEV01 also decreased the expression of CD36, a potential target for cancer therapy, in glioma and liver cancer cells. In an in vivo glioma-induced model, AEV01 exhibited anti-tumor effects and reduced the expression of CD36. Histopathological analysis demonstrated that AEV01 had minimal toxicity on vital organs. Overall, these findings suggest that AEV01 has potential as a therapeutic agent for glioma and liver cancer.

show abstract

Evaluating the Anti-Tumor Efficacy and Safety of AEV01 in Glioblastoma and Hepatocellular Carcinoma: AnIn VitroandIn VivoApproach

Biswas,

Precilla S,

Kumar

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Evaluating the Anti-Tumor Efficacy and Safety of AEV01 in Glioblastoma and Hepatocellular Carcinoma: An In Vitro and In Vivo Approach

Biswas,

Kumar

et al. 2024

Preprint

View full text Add to dashboard Cite

Gliomas and hepatocellular carcinoma (HCC) are aggressive cancers with poor prognoses, often leading to less than a year of survival. Therapeutic resistance underscores the need for novel therapeutic strategies. AEV01, derived from Picrorhiza kurroa, has shown promise as a potential anticancer agent. In this context, the current study aimed to evaluate the anti-tumor efficacy and safety profile of AEV01 both in vitro and in vivo in glioblastoma and HCC models. Briefly, cytotoxicity and apoptosis were assessed using MTT assays and AO/EtBr staining, while ELISA and immunofluorescence measured inflammatory markers, TP53 and CD36 expression. In vivo, ELISA was performed against the inflammatory and tumor suppressor markers while, histopathological analysis assessed tumor morphology and organ toxicity. AEV01 exhibited dose-dependent cytotoxicity against U-87 MG glioblastoma and HepG2 liver cancer cells, with optimal concentrations at 400 µg and 300 µg respectively. Treatment downregulated inflammatory markers, CD36 expression and concomitantly increased TP53 expression. Xenograft models depicted similar results, with reduced tumor markers expression, reduced tissue architecture, and no significant organ toxicity. Thus, AEV01 demonstrated potent anti-tumor activity with a favorable safety profile, suggesting its potential as a novel therapeutic agent for gliomas and HCC, warranting further clinical investigation.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A randomized, placebo controlled, double blinded, parallel group clinical study to evaluate the efficacy and safety of AEV01 along with standard care for elderly patients with mild COVID-19

Cited by 2 publications

References 25 publications

Evaluating the Anti-Tumor Efficacy and Safety of AEV01 in Glioblastoma and Hepatocellular Carcinoma: AnIn VitroandIn VivoApproach

Evaluating the Anti-Tumor Efficacy and Safety of AEV01 in Glioblastoma and Hepatocellular Carcinoma: AnIn VitroandIn VivoApproach

Evaluating the Anti-Tumor Efficacy and Safety of AEV01 in Glioblastoma and Hepatocellular Carcinoma: An In Vitro and In Vivo Approach

Contact Info

Product

Resources

About